Articles

mesh

Engaging communities with clinical trials in Malawi.

by Debora Nyirenda and Sharon Nkhwazi

  The Malawi–Liverpool–Wellcome (MLW) programme was established in 1995 and is based at Queen Elizabeth Central Hospital in Blantyre. It conducts high-quality research on major health challenges ranging from malaria, ...

News

The CEPI Centralized Laboratory Network (CLN) has expanded

Two leading scientific organizations, IVI and KDCA, have officially joined the CLN

CEPI is pleased to announce that two leading scientific organizations, the International Vaccine Institute (IVI) and the Korea Disease Control and Prevention Agency (KDCA), have officially joined the CLN. The network now comprises 20 facilities... Read more

CEPI launches a Call for Proposal for innovative analytical technologies to improve vaccine manufacturing speed and equitable access

Deadline for application: 1 May 2026. An application may be submitted at any time; the review process will involve quarterly reviews throughout the 12-month application period

CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more

CEPI launches its first ever Biosecurity Request for Proposals (RfP)

Biosafety and biosecurity capacity strengthening in support of the 100 Days Mission RfP. Deadline for application: 30 July 2025

CEPI hopes to identify a group of implementing partners who can help achieve its Biosecurity Strategy. CEPI is looking for partners who can support different types of activities, across diverse geographic settings, related to its biosecurity objectives Read more

Scientists at Denmark’s AdaptVac lead pioneering research to develop an all-in-one vaccine against deadly filoviruses

CEPI and the EU’s Horizon Europe programme are funding the development of a single vaccine to protect against Ebola viruses, Marburg, and other filoviruses

A global consortium led by Danish biotech AdaptVac is developing a vaccine that combines AI-designed immunogens, components that trigger immune response, with AdaptVac’s virus-like particle platform, which mimics real viruses to safely stimulate immunity against multiple deadly filoviruses. Read more

CEPI has launched the Research Preparedness Program (RPP)

The RPP will support both advanced-stage clinical development of CEPI’s portfolio vaccines against priority diseases and the 100 Days Mission

The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more

Older News Here |